Therma Bright's Investment Partnership InStatin Joins Forces with InVixa to Enhance Its Patent Portfolio For The Development Of Innovative Respiratory Solutions
Therma Bright announces a strategic partnership between its investment partners InStatin and InVixa. InVixa will assign its exclusive worldwide licensing agreement for inhaled statin solutions to InStatin, pending University of California, Davis approval. InStatin will issue 160,000 shares to InVixa shareholders, increasing Therma Bright's stake to approximately 20%. InStatin is initiating a Series A funding round to advance its statin inhalant solution for asthma and COPD. The global asthma treatment market is projected to reach $30.1 billion by 2030, while the lung disease therapeutics market is expected to grow from $83.4 billion in 2023 to $152.4 billion by 2033.
Therma Bright annuncia una partnership strategica tra i suoi partner d'investimento InStatin e InVixa. InVixa assegnerà il suo accordo di licenza esclusivo a livello mondiale per soluzioni di statine inalate a InStatin, in attesa dell'approvazione dell'Università della California, Davis. InStatin emetterà 160.000 azioni agli azionisti di InVixa, aumentando la partecipazione di Therma Bright a circa il 20%. InStatin sta avviando un round di finanziamento di Serie A per promuovere la sua soluzione di statina inalata per asmatici e pazienti con BPCO. Si prevede che il mercato globale del trattamento dell'asma raggiunga i 30,1 miliardi di dollari entro il 2030, mentre il mercato delle terapie per le malattie polmonari dovrebbe crescere da 83,4 miliardi di dollari nel 2023 a 152,4 miliardi di dollari entro il 2033.
Therma Bright anuncia una asociación estratégica entre sus socios de inversión InStatin e InVixa. InVixa asignará su acuerdo de licencia mundial exclusivo para soluciones de estatinas inhaladas a InStatin, a la espera de la aprobación de la Universidad de California, Davis. InStatin emitirá 160.000 acciones a los accionistas de InVixa, aumentando la participación de Therma Bright a aproximadamente el 20%. InStatin está iniciando una ronda de financiamiento de la Serie A para avanzar en su solución de estatina inhalada para asma y EPOC. Se proyecta que el mercado global de tratamientos para el asma alcance los 30.1 mil millones de dólares para 2030, mientras que se espera que el mercado de terapias para enfermedades pulmonares crezca de 83.4 mil millones de dólares en 2023 a 152.4 mil millones de dólares para 2033.
Therma Bright는 투자 파트너 InStatin과 InVixa 간의 전략적 파트너십을 발표했습니다. InVixa는 캘리포니아 대학교 데이비스의 승인을 전제로 흡입용 스타틴 솔루션에 대한 독점적인 전 세계 라이선스 계약을 InStatin에 부여할 것입니다. InStatin은 InVixa 주주에게 160,000주의 주식을 발행하여 Therma Bright의 지분을 약 20%로 늘릴 것입니다. InStatin은 천식 및 COPD를 위한 스타틴 흡입 솔루션을 추진하기 위해 시리즈 A 자금 조달 라운드를 시작하고 있습니다. 글로벌 천식 치료 시장은 2030년까지 301억 달러에 이를 것으로 예상되며, 폐 질환 치료 시장은 2023년 834억 달러에서 2033년까지 1524억 달러로 성장할 것으로 보입니다.
Therma Bright annonce un partenariat stratégique entre ses partenaires d'investissement InStatin et InVixa. InVixa attribuera son accord de licence exclusif mondial pour des solutions de statines inhalées à InStatin, en attente de l'approbation de l'Université de Californie, Davis. InStatin émettra 160 000 actions aux actionnaires d'InVixa, augmentant la participation de Therma Bright à environ 20%. InStatin lance un tour de financement de série A pour faire progresser sa solution de statine inhalée pour l'asthme et la BPCO. Le marché mondial du traitement de l'asthme devrait atteindre 30,1 milliards de dollars d'ici 2030, tandis que le marché des thérapies pour les maladies pulmonaires devrait passer de 83,4 milliards de dollars en 2023 à 152,4 milliards de dollars d'ici 2033.
Therma Bright kündigt eine strategische Partnerschaft zwischen seinen Investmentpartnern InStatin und InVixa an. InVixa wird sein exklusives weltweites Lizenzabkommen für inhalierte Statinlösungen an InStatin übertragen, vorbehaltlich der Genehmigung der Universität von Kalifornien, Davis. InStatin wird 160.000 Aktien an die Aktionäre von InVixa ausgeben, wodurch der Anteil von Therma Bright auf etwa 20% steigen wird. InStatin startet eine Serie-A-Finanzierungsrunde, um seine inhalierbare Statinlösung für Asthma und COPD voranzubringen. Der globale Markt für Asthmabehandlungen wird bis 2030 voraussichtlich 30,1 Milliarden Dollar erreichen, während der Markt für Therapien bei Lungenerkrankungen von 83,4 Milliarden Dollar im Jahr 2023 auf 152,4 Milliarden Dollar im Jahr 2033 wachsen soll.
- Therma Bright's stake in InStatin increases by 3% to approximately 20%
- InStatin secures exclusive worldwide licensing for inhaled statin solutions
- Company positioned in growing markets: asthma ($30.1B by 2030) and lung disease therapeutics ($152.4B by 2033)
- Product still in early development stage, pending preclinical studies and Phase 1 trials
- Future dilution expected from upcoming Series A funding round
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung disease
Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce a significant development with its investment partners, InStatin and InVixa. InVixa will assign its licensing agreement to InStatin, contingent upon approval from the University of California, Davis.
The collaboration marks a pivotal step in the integration of these two businesses. This strategic move of InVixa assigning InStatin with an exclusive, worldwide licensing agreement for it inhaled statins to prevent and treat acute lung disease is expected to bolster InStatin's intellectual property portfolio. InStatin in return will issue 160,000 InStatin shares to InVixa's shareholders, further solidifying the partnership and aligning their interests as they advance both their innovative respiratory solutions.
Therma Bright stake in InStatin will increase by
"This collaboration is particularly focused on addressing critical healthcare challenges, including asthma and acute lung disease," shared Ijaz Khan, President of InStatin. "The exclusive worldwide license for InVixa's inhaled statin solution to prevent and treat acute lung disease fits nicely and makes perfect sense for InStatin's own IP portfolio around statin inhalant solution for asthma and COPD."
The global market for asthma treatment is projected to reach USD
"We're pleased that InVixa and InStatin have initiated this worldwide licensing agreement;" expressed Rob Fia, CEO of Therma Bright. "The opportunity that both solutions bring to individuals suffering from these respiratory diseases is very exciting. Furthermore, it offers our shareholders a wonderful opportunity to participate in a space that is expected to experience solid growth over the next decade."
Therma Bright's investments in InStatin, and InVixa are poised to revolutionize asthma, COPD and acute lung disease treatments with their innovative inhalant solutions, aiming to provide both consumers and medical professionals with effective, high-quality options to combat these pressing health issues.
In other news, Therma Bright is working closely with Quantify Medical on the trial of Venowave VW5 device sales and Medicare/Medicaid HCPCS Level II code E0683 reimbursement program. The Company will provide an update to the marketplace upon completion of Quantify Medical's trial through its medical and healthcare practitioner provider network.
About Therma Bright Inc. Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on:
Twitter
FORWARD-LOOKING STATEMENTS Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as progressing clinical trials at InStatin, and the sales trial of Venowave and related information as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228001
FAQ
What is the new licensing agreement between InStatin and InVixa for TBRIF?
How much will Therma Bright's stake in InStatin increase after the deal?
What is the projected market size for asthma treatment by 2030 relevant to TBRIF?
